Karyopharm Therapeutics (KPTI) Shares Outstanding (Weighted Average) (2012 - 2025)

Karyopharm Therapeutics has reported Shares Outstanding (Weighted Average) for 13 years, with the latest figure at $10.2 million in Q4 2025.

• For the quarter ending Q4 2025, Shares Outstanding (Weighted Average) rose 176.36% year-over-year to $10.2 million; the trailing twelve-month figure through Dec 2025 stood at $10.2 million (up 176.36% YoY), and the FY2025 full-year result was $10.2 million, up 176.36% from the prior year.
• Shares Outstanding (Weighted Average) for Q4 2025 stood at $10.2 million, up from $8587.0 in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $113.8 million in Q2 2023, with the low at $7700.0 in Q1 2024.
• Historically, Shares Outstanding (Weighted Average) has averaged $38.9 million across 5 years, with a median of $7.0 million in 2024.
• Annual changes were most pronounced in 2021 — Shares Outstanding (Weighted Average) jumped 110088.24% — and 2024, when it tumbled 99.99%.
• Karyopharm Therapeutics' Shares Outstanding (Weighted Average) stood at $75.2 million in 2021, then tumbled by 99.89% to $81871.0 in 2022, then soared by 696.83% to $652370.0 in 2023, then soared by 467.79% to $3.7 million in 2024, then jumped by 176.36% to $10.2 million in 2025.
• The last three Shares Outstanding (Weighted Average) figures came in at $10.2 million (Q4 2025), $8587.0 (Q3 2025), and $8620.0 (Q2 2025), per Business Quant data.